SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Presidio Medical, Inc., a clinical-stage medical device company developing a neuromodulation platform, today announced that Katherine H. Neuenfeldt has joined the Executive Team as Vice President, Marketing.
Ms. Neuenfeldt is a commercial leader with 20 years of experience in the healthcare industry. She spent over six years at Nevro leading both Market Access and Marketing functions as Nevro grew from a small, private company to a disruptive and established player. Ms. Neuenfeldt led the highly successful U.S. product launch that transformed the SCS market, created sustainable product differentiation, and played a key role in scaling the organization during its years of rapid revenue growth. Ms. Neuenfeldt also led multiple high-profile product launches while at Medtronic Endovascular that led to double digit revenue growth and market leadership positions. Prior to 2008, Ms. Neuenfeldt held roles at Johnson & Johnson, HealthTech, and Triage Consulting Group. Ms. Neuenfeldt received a B.A. in Human Biology from Stanford University, a M.S. in Epidemiology from the Stanford School of Medicine, and a M.B.A. from the Darden School of Business at the University of Virginia.
“We are thrilled to welcome Katherine to our leadership team,” said Michael Ackermann, co-founder and Chief Executive Officer of Presidio Medical. “Her unique experience leading multiple commercial functions and her proven track record in launching innovative medical devices will better enable us to deliver this transformational platform to patients around the world.”
Presidio Medical’s technology is designed to provide pain relief across a broad spectrum of pain types where conventional treatment has failed. The company is also researching the application of its novel technology for additional indications across several therapeutic areas with significant unmet medical needs. Presidio Medical was founded in 2017 and its investors include Invus Opportunities and Action Potential Venture Capital.
Invus Opportunities is a sister fund to The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Invus Opportunities is focused on partnering with market-leading management teams and investors in private transactions globally. With a differentiated heritage and capital base, Invus Opportunities brings a complementary dimension to growing companies and investor groups seeking to create lasting value. Invus Opportunities both leads rounds of financing and co-invests in syndicated financings, and currently manages over $2 billion.
Action Potential Venture Capital
Action Potential Venture Capital (APVC) is a GlaxoSmithKline (GSK) backed venture fund dedicated to investments in the field of Bioelectronic Medicines. This emerging therapeutic field includes both non-invasive and minimally invasive devices that use energy as a medicine to elicit cellular response (e.g., nerve signaling) to improve organ function as therapies for chronic diseases. APVC also invests more broadly in the enabling technologies that deliver this precision energy as a medicine. For more information about APVC visit www.actionpotentialvc.com.
Presidio Medical was founded in 2017 and is headquartered in South San Francisco. The clinical-stage, privately held medical device company, is developing a transformational neuromodulation technology platform with a first indication in the treatment of chronic pain. For more information, visit www.presidiomedical.com.